Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Sep 25, 2026
Ideaya Biosciences, Inc. (IDYA)
A forensic read on Ideaya Biosciences, Inc. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
F · Poor — capital at risk
Forensic grade
Safe
Financial health
13.1
Distress distance
Clean
Earnings quality
3
Forensic signals
-20.0
P / E (ttm)
-11.1%
ROE
$3.6B
Market cap
0.00%
Dividend yield
3024.4%
Revenue growth
This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (red flags, auditor quality, say on pay, board independence, going concern, valuation). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.
Ideaya Biosciences, Inc. earns an F (Poor — capital at risk) forensic quality grade, and its balance-sheet distress test reads 13.1, placing it in the Safe zone. 3 forensic signals were flagged in its latest SEC filings, led by return on invested capital.
What the filings flag
-13.4%
FY2025
Return on invested capital.Return on invested capital is -13.4% in the latest fiscal year. $937M of the $938M base at FY2025 is short-term investments and long-term marketable securities (99.9%) — securities held beside cash, which the base keeps because only cash is subtracted from it; they earn the balance sheet's yield, which is not in the operating profit above, so the loss on the operating capital is larger than this rate shows.
+24.0%/yr
FY2023–FY2025
Share-count dilution.Diluted share count changed +54% over the last 2 years to FY2025 (+24.0%/yr). The count is growing — 57.5M shares in FY2023, 88.5M in FY2025: more stock was issued than repurchased over this window, so aggregate results grew faster than their per-share equivalents. That's ~24.0% shaved off per-share growth every year — total profit has to grow that much just to keep earnings-per-share flat, and a stake held since FY2023 has been diluted ~35%.
21% of rev
FY2025
Stock-based comp load.Stock-based compensation ran 21% of revenue in FY2025 — about $0.52 per diluted share. No cash left the business to pay it, which is why operating cash flow adds it back. Net of repurchases the diluted count still rose about 24.0% a year across FY2023–FY2025, and the rate is falling. Stock compensation is one source of that issuance; acquisition consideration, equity raises, convertibles and other employee plans also net into the count, and these figures do not separate them.
Key fundamentals
Latest Revenue$218.7M
Revenue Growth YoY+3024.4%
Revenue CAGR (2yr)+205.6%
Net Margin-52.0%
Free Cash Flow-$73.5M
Return on Equity-11.1%
The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Ideaya Biosciences, Inc.'s actual 10-K/10-Q/8-K filings?